Iqvia (IQV) Price Target Raised to $145.00 at Morgan Stanley

Share on StockTwits

Iqvia (NYSE:IQV) had its price objective upped by Morgan Stanley from $130.00 to $145.00 in a research note released on Monday. The firm currently has an overweight rating on the medical research company’s stock.

Several other research analysts also recently weighed in on the company. Zacks Investment Research downgraded Iqvia from a buy rating to a hold rating in a research note on Thursday, October 25th. Royal Bank of Canada upped their price target on Iqvia to $137.00 and gave the stock an outperform rating in a research note on Tuesday, October 23rd. Piper Jaffray Companies upped their price target on Iqvia to $131.00 and gave the stock a neutral rating in a research note on Tuesday, October 23rd. Barclays upped their price target on Iqvia from $130.00 to $140.00 and gave the stock an overweight rating in a research note on Tuesday, October 23rd. Finally, UBS Group began coverage on Iqvia in a research note on Tuesday, October 9th. They issued a buy rating for the company. Five research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $134.41.

IQV stock opened at $121.85 on Monday. Iqvia has a 1-year low of $91.57 and a 1-year high of $135.48. The company has a quick ratio of 1.09, a current ratio of 1.09 and a debt-to-equity ratio of 1.41. The company has a market capitalization of $24.64 billion, a price-to-earnings ratio of 27.73, a price-to-earnings-growth ratio of 1.77 and a beta of 0.81.

Iqvia (NYSE:IQV) last posted its quarterly earnings results on Monday, October 22nd. The medical research company reported $1.42 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.39 by $0.03. Iqvia had a return on equity of 13.69% and a net margin of 12.29%. The business had revenue of $2.59 billion during the quarter, compared to the consensus estimate of $2.58 billion. Iqvia’s revenue was up 5.2% compared to the same quarter last year. On average, sell-side analysts expect that Iqvia will post 5.13 EPS for the current fiscal year.

In other news, CFO Michael R. Mcdonnell sold 9,500 shares of the stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $128.35, for a total transaction of $1,219,325.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Group Holdings (Sbs) Advis Tpg sold 3,573,545 shares of the stock in a transaction that occurred on Tuesday, December 4th. The shares were sold at an average price of $123.72, for a total value of $442,118,987.40. The disclosure for this sale can be found here. Insiders have sold a total of 7,117,903 shares of company stock valued at $881,082,166 over the last quarter. Corporate insiders own 6.00% of the company’s stock.

Large investors have recently added to or reduced their stakes in the stock. Cutler Group LP raised its holdings in Iqvia by 173.3% during the 2nd quarter. Cutler Group LP now owns 1,100 shares of the medical research company’s stock valued at $109,000 after buying an additional 2,600 shares during the period. Fort L.P. purchased a new stake in Iqvia during the 2nd quarter valued at $118,000. Hamilton Lane Advisors LLC purchased a new stake in Iqvia during the 3rd quarter valued at $121,000. Point72 Hong Kong Ltd raised its holdings in Iqvia by 2,115.9% during the 3rd quarter. Point72 Hong Kong Ltd now owns 975 shares of the medical research company’s stock valued at $126,000 after buying an additional 931 shares during the period. Finally, Quad Cities Investment Group LLC purchased a new stake in Iqvia during the 2nd quarter valued at $140,000. Institutional investors own 89.33% of the company’s stock.

Iqvia Company Profile

IQVIA Holdings Inc provides integrated information and technology-enabled healthcare services in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Commercial Solutions, Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offers a range of cloud-based applications and related implementation, real-world insights, and reference information services; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services.

Recommended Story: Do stock splits help investors?

Analyst Recommendations for Iqvia (NYSE:IQV)

Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Highland Capital Management LP Purchases 1,000 Shares of Zoetis Inc
Highland Capital Management LP Purchases 1,000 Shares of Zoetis Inc
Highland Capital Management LP Acquires Shares of 75,000 Forum Merger Corp
Highland Capital Management LP Acquires Shares of 75,000 Forum Merger Corp
Highland Capital Management LP Buys Shares of 50,000 Direxion Daily S&P 500 Bear 3X Shares
Highland Capital Management LP Buys Shares of 50,000 Direxion Daily S&P 500 Bear 3X Shares
Pacer Advisors Inc. Boosts Stake in DowDuPont Inc
Pacer Advisors Inc. Boosts Stake in DowDuPont Inc
Pacer Advisors Inc. Has $9.74 Million Position in Citigroup Inc
Pacer Advisors Inc. Has $9.74 Million Position in Citigroup Inc
The Manufacturers Life Insurance Company Has $522.94 Million Position in Morgan Stanley
The Manufacturers Life Insurance Company Has $522.94 Million Position in Morgan Stanley


Leave a Reply

 
© 2006-2018 Zolmax.